CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $18 | -99.9% | 1,000 | 0.0% | 0.00% | – |
| Q3 2022 | $19,000 | -89.3% | 1,000 | -85.8% | 0.00% | -100.0% |
| Q4 2019 | $177,000 | +293.3% | 7,066 | +134.5% | 0.00% | +100.0% |
| Q3 2019 | $45,000 | -43.0% | 3,013 | -4.7% | 0.00% | 0.0% |
| Q2 2019 | $79,000 | +9.7% | 3,161 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $72,000 | -24.2% | 3,161 | 0.0% | 0.00% | -50.0% |
| Q4 2018 | $95,000 | +4.4% | 3,161 | 0.0% | 0.00% | +100.0% |
| Q3 2018 | $91,000 | – | 3,161 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |